Fabtech Technologies Limited conducted an investor meet titled 'The Growth Exchange 2026 – Niveshak Samvad Roadshow' on June 24, 2026, in Mumbai. The meeting served as a platform for company officials to engage with analysts and investors. The discussion was restricted to publicly available information, ensuring no unpublished price-sensitive information was disclosed.

The session took place physically from 05:30 p.m. to 06:30 p.m. IST. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The filing was submitted to the National Stock Exchange of India Limited and BSE Limited on June 25, 2026. Hemant Mohan Anavkar, Executive Director, signed the disclosure on behalf of Fabtech Technologies .

Fabtech Technologies Limited reported a 25.7% year-on-year increase in standalone revenue to ₹410.77 Cr for the year ended March 31, 2026, while announcing new strategic initiatives including a ₹49.00–52.00 Cr North Africa veterinary facility and an EU GMP plant aimed at supporting exports. Operational profit rose 17% to ₹36.60 Cr, and the company maintained a confirmed order book of ₹900+ Cr, providing strong revenue visibility for coming periods. The firm is targeting standalone revenue of ₹500 Cr and a profit after tax (PAT) of ₹45 Cr for FY27, driven by a robust enquiry pipeline and strategic expansion into premium markets.

Key Financial Metrics

The following table summarises Fabtech Technologies' latest financial performance and near-term targets:

New Strategic Wins and Expansion Projects

Fabtech Technologies has identified a North Africa veterinary facility valued at ₹49.00–52.00 Cr as a key near-term target, adding to its pipeline of international projects. The company is also pursuing an EU GMP plant designed to support exports, which is expected to strengthen its brand presence and margins in regulated markets. These initiatives complement recent strategic wins, including a USD 7.05M oral solid dosage facility in West Africa and a USD 7.8M animal vaccine project in Saudi Arabia, underscoring the company's growing footprint in specialised pharmaceutical and veterinary infrastructure.

Growth Strategy and Market Focus

The company's growth strategy focuses on three primary levers: a European acquisition to strengthen brand presence and margins, joint ventures in Saudi Arabia and Africa, and improved working-capital strength to enable faster project acquisition. Management highlighted that 78% of revenue is derived from MENA, GCC & ECO Zone markets, supported by an asset-light model that scales through in-house arms and strategic partners. By securing domestic status in the UAE and Saudi Arabia, the company unlocks natural tax advantages and eligibility for local-content tenders.

Margin Expansion Roadmap

Fabtech Technologies is executing a margin expansion roadmap targeting a PAT margin increase from the current 8–9% to 11–13%. This will be achieved through localisation benefits, alternative sourcing, and taking on the pre-engineered building (PEB) scope to control civil works and project timelines. The company has delivered 500+ projects across 62+ countries, establishing a reference-led moat with landmark facilities such as the largest IV solution facility in Saudi Arabia and the first biosimilars facility in Algeria.

Long-Term Vision

The investor presentation, submitted to exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlined a 15-year structural opportunity driven by regional medicinal sovereignty. The company's long-term vision, FTL 2030, aims to climb the value curve into advanced-technology facilities including medical diagnostics, vaccines, biotech, and cell & gene therapy. The disclosure was made by Hemant Mohan Anavkar, Executive Director.